لټون (خبرونه)

Longeveron Announces Constructive Type C Meeting With U.S. FDA Ahead Of Data Readout For ELPIS II Phase 2B Clinical Trial Evaluating Treatment For Hypoplastic Left Heart Syndrome (HLHS)

english top health

(MENAFN - GlobeNewsWire - Nasdaq) MIAMI, May 08, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies ...
2026-05-08 16:14:34